PROMOTING THE CREATION RELOCATION AND DEVELOPMENT OF BIOTECH

PROMOTING THE CREATION, RELOCATION AND DEVELOPMENT OF BIOTECH COMPANIES 1

Genopole®: From a Bio-Park to a Bio-Cluster. . . A continuum dedicated to Biotechnology Research Companies Hospital University 2

Genopole® : a Biopark fully integrated in the Medicen Paris Region Bio-cluster v. Non-Profitable Organisation ü Incorporated in 1998 CEO Deputy ü Creation & Development of a Bio-Park : Companies & Research Labs General Affairs International Affairs Communication Research Platforms Companies Micell. 18% Region 39% State 17% Council 26% 30 Km 3

Genopole®: Building the most favorable environment to develop Biotech companies… International Scientific Network environment Versatile Real Estate Offers and Services Biotech Companies Pre seed Fund Shared Clinical Technical platforms Network Incubation and development Programs 4

Genopole®: A stimulating Collaborative Scientific & Education Environment rch sea Re v 20 research labs, incl. 3 national-scale centres ü More than 900 scientists ü From major National Research Agencies o … v. Evry University and 3 engineer schools ü more than 12, 000 students (34 % in wet sciences and engineering) and 400 professors v. Ambitious Integrative Programs ü i. Stem : Institute for Stem Cells (2005) ü i. SSB : Institute for Systems and Synthetic Biology (2009) ü Institute for Biomaterials (2010) 5

Genopole®: a new hospital and a center for clinical and translational research Cli nic al v. A new hospital is build on Genopole® campus ü Latest & Largest General Hospital build in France ü 1, 000 beds ü Opening May 2011 v. Genopole coordinates the construction of a center for clinical and translational research ü 3, 000 m² ü New Approaches ü Opening late 2011

Genopole®: more than 83 000 m² dedicated to the development of life science companies ate Real Est Our facilities include space from “plug ‘n play” offices for entrepreneurs to customised tenant lab & office spaces v. Business Center (20 -50 m²): ü Offices fully furnished, Meeting rooms, . . . v. Incubator with shared laboratory equipment ü for 50 to 300 m² wet lab & office suites ü Fully equipped with benches, sinks, deionised water, autoclave, freezers, rt-PCR, … vcustomized spaces / specific demand lay out ü for 300 to 2 000 m² and more wet lab, L 2 & office suites 7

Genopole®: State of the art shared technical platforms and equipment es tur ruc ast r Inf v. Sharing expertise, skills and resources ü 15 Platforms/Equipments end 2009 ü Management : 13 public labs, 1 private and 1 Genopole ü Genopole investments ~ 20 M€ ü Headcount : 68 persons ü Cumulated surface ~ 4200 m 2 ü 5 obtained national quality label ü 2 ISO 9001 v 2000 certification & 2 planned in 2009 -2010 ü more than 300 scientific publications ü 8 patents/licences 8

Genopole®: State of the art shared technical platforms and equipment es tur uc str ra Inf v v v 15 Platforms v v v v v CERFE and CERFAP(Animal facilities) Cell and Small Animal Irradiator Imaging and cytometry platform Bioinformatic annotation DNA chips production Mass spectrometry platform Evr@Platform (augmented reality and virtual environment) Plant DNA Microarray platform Biophotonics Platform Structural Biology Platform (NMR, AFM) Transmission electron microscopy DNA and cells Bank HTS Platform Cell sorting station Incubator shared equipements 9

Genopole®: GMP production centers for drugs of the future es tur uc str ra Inf The Present & the Future ü A GMP compliant biomanufacturing center for proteins from mammalian cells (biotherapy, monoclonal antibodies) ü A GMP compliant viral vector bioproduction center (Genethon) ü A production centre of enzymes and biocatalysis for industrial use. ü A GMP biomanufacturing centre using alternative techniques : bacteria, yeast, plants… ü An GMP oligonucleotides production center in partnership ü A Laboratory to develop and optimise the best expression systems ü A centre for filling, packaging and delivering products under GMP compliant 10

Genopole®: a team dedicated to foster creation and development of biotech companies Incubation Finance 6 4 2 0 Market Compet. Bus Dev IP Science(s) Clinic&Reg Scale up Team v. A Team of 6 multidisciplinary Managers Finance 6 Project 4 Market 2 Compet Bus Dev 0 ü Combining solid complementary backgrounds in pre-incubation, IP, finance, valuations, biz. dev. , fund raising, licensing, … Science(s) Clinic&Reg Scale up IP Team

Genopole®: a team dedicated to foster creation and development of biotech companies… Incubation - Tailor-made Incubation Programs - v. Development Phase v. Incorporation Phase ü Access to the Best R&D tax Credit in Europe ü Cover 50% of all R&D costs in the 1 st year ü 40% the 2 nd year and 30% in subsequent years up to € 100 million and 5% above ü Legal support for corporate development ü Raise Public Money ü Direct relations with OSEO, CFI, ANR, Medicen, … ü Drug Development ü Network of preclinical & clinical experts ü Access to French and European authorities: AFSSAPS or EMEA ü Raise Private Money ü Network of BAs and VCs ü Business Development ü Direct Access to all French Tech Transfer Offices (CNRS, Inserm, CEA, AP-HP, …) ü Network of business opportunities ü Network of international experts

Genopole®: a list of services to foster the development of Biotech companies Incubation v. Genopole provides a whole list of services dedicated to young biotech companies ü Senior administrative officers, Accounting, quality assurance, onsite IT network support, human resources management, … v. Genopole coordinates an European Grant Service dedicated to SMEs. . . ü au e e ® ur rop le B u o E op en G Brings support to preparation and application phases but also in the management of funded project v. Genopole organises access to : ü Electronic libraries including scientific and competitive databases ü Annual Calls for Equipments and Post-Docs

Genopole®: with G 1 J Id. F access to a pre-seed Fund Incubation v. G 1 J - Genopole pre-seed Life Sciences Capital Fund üInitial Capital: 2. 1 M€ - 16 private investors üInvestment/project: 50 000 – 100 000 € « From 1 st day to 1 st round of financing » Allows access to the Oseo grant system and to National, Regional & EU grants v. G 1 J - Genopole Regional Life Sciences Capital Fund ü Equity raise: 6 M€ ü brings G 1 J to the Proof of Concept Fund level ü Investment/project: 300 000 – 500 000 €

Genopole®: More than 80 currently incorporated companies and active projects … GENOPOLE® ENTREPRISES in 2008 LTK Pharma 69 biotech companies Texcell Global. Bio Energy 1023 FTE 207. 81 M€ fund raised 144. 11 M€ sales / 30 companies Nano. BH 670 granted/penting patents 28 products from IND to Phase III & market 15

Genopole®: an international network oriented to biotech companies International v. Genopole manages an international network ü with international Cies, pharma laboratories, foreign bioincubators and international venture capital institutions, v. Genopole is member of several European consortium with European bioparks ü Bio. Link (FP 5) Oxford, Munich, Cagliari, Jerusalem, Cardiff ü Natibs (FP 6) Berlin, Barcelona, Karolinska, Tallinn, Tel Aviv, Inno ü CEBR (FP 6) Cambridge, Oxford, Berlin, Munich, Heidelberg, Barcelona, Uppsala, Tallinn, Lyon ü Bio-CT (FP 7) Torino, Cambridge (CEBR), Barcelona, Berlin, Debrecen & Inno

Genopole® Campus 1 Today & tomorrow Centre de Bioproduction Restaurant inter-entreprises et Résidence hôtelière 2011 Projet Gamma : production GM P de lots cliniques de vecteurs viraux de Généthon 2011 Genavenir : Pôle d’entreprises et de laboratoires Centre de Recherche Clinique et Translationnelle Pépinière Centre Hospitalier Sud-Francilien 2011 CCIE Genopole Entreprises Projet Crèche 2011 Genavenir : Hôtels d’entreprises

Our achievements. . . § 20 research labs - 900 jobs § 70 biotech companies – 1 000 jobs§ A comprehensive 83 000 m² real estate offer § A team dedicated to development § Services and a Europe Grant service § 17 platforms and equipments § Corbeil Evry Hospital & Clinical and Translational Research Center § GMP Biomanufacturing Center opening soon and 4 others biomanufacturing project running 18

For more Informations … http: //www. genopole. fr Emmanuel DIAZ Economic Development Director Place de l’Agora BP 62 91002 EVRY Cedex Tel + 33 (0)1 69 91 59 38 emmanuel. diaz@agglo-evry. fr www. agglo-evry. fr Caroline Mercier Head of networks and investments Essonne Development Agency 6 cours Monseigneur Roméro 91025 Evry Cedex Fixe : + 33 (0)1 69 91 42 56 mail : caroline. mercier@essonne-developpement. com Delphine Beau Life Sciences Director Paris Region Economic Development Agency www. paris-region. com Tel : (+33 (0)1 58 18 69 62 Mob. : +33 (0)6 03 85 66 32 Eric Lameignère Genopole Entreprises Director 5, rue Henri Desbruères F-91057 Evry Cedex Tel. : +33 (0)160 878 306 Tel : (+33 (0)1 58 18 69 62 Mob. : +33 (0)6 03 85 66 32 Eric. lameignere@genopole. fr 19